Claims
- 1. A nucleic acid sensor molecule, the nucleic acid sensor molecule comprising
a target molecule activation site, the target molecule activation site comprising
a structure that recognizes a target molecule and an optical signaling unit, wherein said optical signaling unit includes at least one nucleotide coupled to a signaling moiety; and wherein said signaling moiety changes its optical properties upon allosteric modulation of said nucleic acid sensor molecule following recognition of said target molecule.
- 2. The nucleic acid sensor molecule of claim 1, wherein said optical signaling unit comprises a first nucleotide coupled to a first signaling moiety and a second nucleotide coupled a second signaling moiety, and wherein said first and second signaling moieties change proximity to each other upon recognition of said target molecule by said target activation site.
- 3. The nucleic acid sensor molecule of claim 2, wherein said first and second signaling moieties comprise a fluorescent label and a fluorescent quencher, and recognition by said nucleic acid sensor of said target molecule results in an increase in detectable fluorescence of said fluorescent label.
- 4. The nucleic acid sensor molecule of claim 2, wherein said first signaling moiety and said second signaling moiety comprise fluorescent energy transfer (FRET) donor and acceptor groups, and recognition by said nucleic acid sensor molecule of said target molecule results in a change in distance between said donor and acceptor groups, thereby changing optical properties of said molecule.
- 5. The nucleic acid sensor molecule of claim 1, wherein said optical signaling unit consists essentially of a first signaling moiety, wherein said first signaling moiety changes conformation upon recognition by said target molecule of said target activation site, thereby resulting in a detectable optical signal.
- 6. The nucleic acid sensor molecule of claim 1, wherein sad nucleic acid sensor molecule includes at least one modified nucleic acid.
- 7. The nucleic acid sensor molecule of claim 1, wherein said nucleic acid sensor molecule is RNA.
- 8. The nucleic acid sensor molecule of claim 1, wherein said nucleic acid sensor molecule is DNA.
- 9. The nucleic acid sensor molecule of claim 4, wherein said nucleic acid sensor molecule is RNA.
- 10. The nucleic acid sensor molecule of claim 1, wherein said target molecule is a polypeptide.
- 11. A method of detecting a target molecule, the method comprising
providing a nucleic acid sensor molecule, the molecule comprising a target molecule activation site, the target molecule activation site comprising a structure that recognizes a target molecule and an optical signaling unit, wherein said optical signaling unit includes at least one nucleotide coupled to a signaling moiety; and wherein said signaling moiety changing its optical properties upon allosteric modulation of said nucleic acid sensor molecule; contacting said nucleic acid sensor molecule with a sample known to contain or suspected of containing a target molecule; and detecting said light signal, wherein said light signal indicates the presence of said target molecule in said population.
- 12. The method of claim 11, wherein said optical signaling unit comprises a first nucleotide coupled to a first signaling moiety and a second nucleotide coupled a second signaling moiety, and wherein said first and second signaling moieties change proximity to each other upon recognition of said target molecule by said target activation site.
- 13. The method of claim 12, wherein said first and second signaling moiety comprise a fluorescent label and a fluorescent quencher, and recognition by said nucleic acid sensor of said target molecule results in an increase in detectable fluorescence of said fluorescent label.
- 14. The method of claim 11, wherein said first signaling moiety and said second signaling moiety comprise fluorescent energy transfer (FRET) donor and acceptor groups, and recognition by said nucleic acid sensor molecule of said target molecule results in a change in distance between said donor and acceptor groups, thereby changing optical properties of said molecule.
- 15. The method of claim 11, wherein said optical signaling unit consists essentially of a first signaling moiety, wherein said first signaling moiety changes conformation upon recognition of said target molecule by said target activation site, thereby resulting in a detectable optical signal.
- 16. The method of claim 11, wherein said target molecule is associated with a pathological condition or genetic alteration.
- 17. The method of claim 11, wherein a plurality of nucleic acid sensor molecules is provided
- 18. The method of claim 17, wherein a plurality of target molecules are detected.
- 19. A diagnostic profile produced by the method of claim 18.
- 20. The diagnostic profile of claim 19, wherein said diagnostic profile is correlated with a wild-type state, a pathological condition, or a genetic alteration.
- 21. A method identifying a nucleic acid sensor molecule, the method comprising
providing a population of oligonucleotides, wherein said population comprises oligonucleotides comprising a first region comprising a random nucleotide sequence; contacting said population with a target molecule; and identifying an oligonucleotide in said population that changes conformation upon recognizing said target molecule.
- 22. The method of claim 21, wherein said oligonucleotides further comprise one or more fixed sequences coupled to said random sequence.
- 23. The method of claim 22, wherein at least one of said fixed sequences includes at least a portion of a catalytic site for catalyzing a chemical reaction.
- 24. The method of claim 23, wherein said catalytic site is selected from the group consisting of a ligase site, self-cleaving site, a Group I catalytic site, a Group II catalytic site, and a hammerhead catalytic site.
- 25. The method of claim 22, wherein at least one of said fixed sequences includes a sequence that facilitates cloning or sequence of said oligonucleotide.
- 26. The method of claim 25, wherein said sequence is selected from the group consisting of a PCR primer site, an RNA polymerase primer activation site, and a restriction endonuclease recognition site.
- 27. The method of claim 21, wherein said oligonucleotide is provided on a replicatable nucleic acid sequence.
- 28. The method of claim 29, wherein said replicatable nucleic acid sequence is a plasmid.
- 29. The method of claim 23, wherein said random sequence includes a target activation site with the random sequence, wherein said catalytic sequence is activated upon recognition of said target molecule to said target activation site.
- 30. The method of claim 23, wherein said method further comprises
(i) identifying target-molecule independent catalytic oligonucleotides in said population that have catalytic activity in the absence of said target molecule; (ii) removing said oligonucleotides from said population prior to contacting said population with said target molecule; and, optionally, repeating steps (i) and (ii).
- 31. The method of claim 23, wherein said method comprises
(i) identifying target-molecule dependent catalytic oligonucleotides in said population, wherein said target-molecule dependent catalytic oligonucleotides have catalytic activity upon recognizing said target molecule; (ii) removing said target-molecule dependent catalytic oligonucleotides from said population of oligonucleotides; and, optionally, repeating steps (i) and (ii).
- 32. The method of claim 30, wherein said method comprises
(i) identifying target-molecule dependent catalytic oligonucleotides in said population, wherein said target-molecule dependent catalytic oligonucleotides have catalytic activity upon recognizing said target molecule; (ii) removing said target-molecule dependent catalytic oligonucleotides from said population of oligonucleotides; and, optionally, repeating steps (i) and (ii).
- 33. The method of claim 23, wherein said fixed sequence is a portion of a catalytic site, and said catalytic site is non-functional.
- 34. The method of claim 33, wherein said oligonucleotide includes a 3′ nucleotide couplable to a first signaling moiety and a 5′ moiety couplable to a second signaling moiety, wherein said first and second signaling moieties change proximity to each other upon recognition of said target molecule by said target activation site.
- 35. The method of claim 34, wherein said first and second signaling moieties comprise a fluorescent label and a fluorescent quencher, and allosteric modulation of said nucleic acid sensor following recognition of said target molecule results in an increase in detectable fluorescence of said fluorescent label.
- 36. The method of claim 34, wherein said first signaling moiety and said second signaling moiety comprise fluorescent energy transfer (FRET) donor and acceptor groups, and allosteric modulation of said nucleic acid sensor molecule following recognition of said target molecule results in a change in distance between said donor and acceptor groups, thereby changing optical properties of said molecule.
- 37. The method of claim 20, wherein said target molecule comprises a polypeptide.
- 38. The method of claim 37, wherein said polypeptide is a secreted polypeptide.
- 39. The method of claim 37, wherein said polypeptide is a membrane-associated polypeptide.
- 40. The method of claim 39, wherein said membrane is a plasma membrane.
- 41. The method of claim 37, wherein said polypeptide is a cytosolic polypeptide.
- 42. The method of claim 37, wherein said polypeptide comprises the amino acid sequence of a nuclear hormone receptor (NHR) polypeptide.
- 43. The method of claim 37, wherein said polypeptide comprises the amino acid sequence of at least a fragment of a G-protein coupled receptor (GPCR) polypeptide.
- 44. The method of claim 43, wherein said GPCR polypeptide is a human GPCR polypeptide.
- 45. The method of claim 43, wherein said polypeptide comprises the amino acid sequence of a ligand-binding portion of a GPCR polypeptide.
- 46. The method of claim 43, wherein said polypeptide comprises the amino acid sequence of a GPCR polypeptide.
- 47. The polypeptide comprises the amino acid sequence of a phosphodiesterase (PDE) polypeptide.
- 48. The method of claim 37, wherein the conformation change of said oligonucleotide upon recognizing said PDE polypeptide is dependent on the presence of a cyclic nucleotide.
- 49. The method of claim 48, wherein said cyclic nucleotide is cAMP.
- 50. The method of claim 48, wherein said cyclic nucleotide is cGMP.
- 51. The method of claim 37, wherein said polypeptide is modified polypeptide.
- 52. The method of claim 37, wherein said polypeptide comprises the amino acid sequence of a phosphodiesterase (PDE) polypeptide or a protein kinase polypeptide (PK).
- 53. The method of claim 52, wherein said PDE or PK polypeptide is a modified PDE or PK polypeptide.
- 54. The method of claim 53, wherein said modified PDE polypeptide or PK polypeptide is a phosphorylated PDE polypeptide.
- 55. The method of claim 53, wherein said oligonucleotide binds with higher affinity to said modified PDE polypeptide or PK polypeptide than to an un-modified PDE or PK polypeptide.
- 56. An oligonucleotide identified by the method of claim 20.
- 57. A plurality of nucleic acid sensor molecules, the plurality comprising two or more nucleic acid sensor molecules, said two or more nucleic acid sensor molecules comprising
a target molecule activation site, the target molecule activation site comprising
a structure that recognizes a target molecule and an optical signaling unit, wherein said optical signaling unit includes at least one nucleotide coupled to a signaling moiety; and wherein said signaling moiety changes its optical properties upon an allosteric modulation of said nucleic acid sensor molecule following recognition of said target molecule.
- 58. The plurality of claim 57, wherein said optical signaling units in said two or more nucleic acid sensor molecules comprise a first nucleotide coupled to a first signaling moiety and a second nucleotide coupled a second signaling moiety, and wherein said first and second signaling moieties change proximity to each other upon allosteric modulation of said target molecule following recognition by said target activation site of said target molecule.
- 59. The plurality of claim 58, wherein said first and second signaling moieties comprise a fluorescent label and a fluorescent quencher, and allosteric modulation of said nucleic acid sensor following recognition of said target molecule results in an increase in detectable fluorescence of said fluorescent label.
- 60. The plurality of claim 59, wherein said first signaling moiety and said second signaling moiety comprise fluorescent energy transfer (FRET) donor and acceptor groups, and allosteric modulation of said nucleic acid sensor molecule following recognition of said target molecule results in a change in distance between said donor and acceptor groups, thereby changing optical properties of said molecule.
- 61. The plurality of claim 57, wherein said optical signaling unit in said two or more nucleic acid sensor molecules consist essentially of a first signaling moiety, wherein said first signaling moiety changes conformation upon recognition of said target molecule to said target activation site, thereby resulting in a detectable optical signal.
- 62. The plurality of claim 57, wherein said two or more biosensor molecules are provided in solution.
- 63. The plurality of claim 57, wherein said two or more biosensor molecules are provided bound to a substrate.
- 64. The plurality of claim 53, wherein said substrate is glass, silicon, nitrocellulose, nylon, or plastic.
- 65. The plurality of claim 57, wherein said attachment is covalent.
- 66. The plurality of claim 57, wherein said attachment is non-covalent.
- 67. The plurality of claim 57, wherein at least two members of said plurality recognizes different target molecules.
- 68. A diagnostic system for detecting a target molecule, the diagnostic system comprising
at least one nucleic acid biosensor, the nucleic acid sensor molecule comprising
a target molecule activation site, the target molecule activation site comprising
a structure that recognizes to a target molecule; and an optical signaling unit, wherein said optical signaling unit includes at least one nucleotide coupled to a signaling moiety; and wherein said signaling moiety changes its optical properties upon allosteric modulation of said nucleic acid sensor molecule following recognition of said target molecule; and a detector in optical communication with said nucleic acid biosensor, wherein said detector detects changes in the optical properties of said nucleic acid biosensor.
- 69. The diagnostic system of claim 68, further comprising a light source in optical communication with said biosensor.
- 70. The diagnostic system of claim 68, further comprising a processor for processing optical signals detected by the detector.
- 71. The diagnostic system of claim 68, wherein said system comprises a plurality of nucleic acid biosensor molecules, wherein at least two of said biosensor molecules recognize two different target molecules.
- 72. A kit for detecting a target molecule, the kit comprising
at least one nucleic acid biosensor, the nucleic acid sensor molecule comprising a target molecule activation site, the target molecule activation site comprising a structure that specifically recognizes a target molecule, and wherein said optical signaling unit comprises a first nucleotide coupled to a first signaling moiety and a second nucleotide coupled a second signaling moiety, and wherein said first and second signaling moieties change proximity to each other upon allosteric modulation by said target molecule to** said target activation site; a reagent for attaching said first signaling moiety; a reagent for attaching said second signaling moiety; and, optionally, control target molecules; and, optionally one or more buffers for analyte detection.
- 73. A method for identifying a drug compound, the method comprising
identifying a nucleic acid biosensor-based molecule profile of target molecules associated with a disease trait in a patient; administering a candidate compound to said patient; and monitoring changes in said profile.
- 74. The method of claim 73, wherein said profile is compared to the profile of a reference population.
- 75. The method of claim 73, wherein said reference population is a healthy population.
- 76. The method of claim 73, wherein said reference population is a diseased population.
- 77. A method for identifying a drug compound, the method comprising
identifying a plurality of pathway target molecules; administering a candidate compound to a patient having a disease trait; and monitoring changes in the structure, level or activity of two or more said plurality of pathway target molecules using a nucleic acid biosensor biomolecule.
- 78. The method of claim 77, wherein said changes are compared to a reference population.
- 79. The method of claim 78, wherein said reference population is a healthy population..
- 80. The method of claim 78, wherein said reference population is a diseased population.
RELATED APPLICATION
[0001] This application claims priority to U.S. Ser. No. 60/232,454, filed Sep. 13, 2000. The contents of this application are incorporated herein by reference in their entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60232454 |
Sep 2000 |
US |